Audeo Oncology (Audeo Oncology) Total Assets : $7.81 Mil (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Total Assets?

Audeo Oncology's Total Assets for the quarter that ended in Sep. 2012 was $7.81 Mil.

Total Assets is connected with ROA %. Audeo Oncology's annualized ROA % for the quarter that ended in Sep. 2012 was -234.52%. Total Assets is also linked to Revenue through Asset Turnover. Audeo Oncology's Asset Turnover for the quarter that ended in Sep. 2012 was 0.01.

Audeo Oncology Total Assets Historical Data

The historical data trend for Audeo Oncology's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Total Assets Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Total Assets

0.12

0.91

9.71

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Total Assets	0.91	1.51	9.71	7.81

Audeo Oncology Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Audeo Oncology's Total Assets for the fiscal year that ended in Jun. 2012 is calculated as

Total Assets	=	Total Equity (A: Jun. 2012 )	+	Total Liabilities (A: Jun. 2012 )
	=	7.033	+	2.679
	=	9.71

Audeo Oncology's Total Assets for the quarter that ended in Sep. 2012 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2012 )	+	Total Liabilities (Q: Sep. 2012 )
	=	2.061	+	5.744
	=	7.81

Audeo Oncology (DELISTED:AURX) Total Assets Explanation

Total Assets is connected with ROA %.

Audeo Oncology's annualized ROA % for the quarter that ended in Sep. 2012 is

ROA %	=	Net Income (Q: Sep. 2012 )	/	( (Total Assets (Q: Jun. 2012 )	+	Total Assets (Q: Sep. 2012 ))	/ count )
	=	-20.54	/	( (9.712	+	7.805)	/ 2 )
	=	-20.54	/	8.7585
	=	-234.52 %

Note: The Net Income data used here is four times the quarterly (Sep. 2012) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Audeo Oncology's Asset Turnover for the quarter that ended in Sep. 2012 is

	Asset Turnover
=	Revenue (Q: Sep. 2012 )	/	( (Total Assets (Q: Jun. 2012 )	+	Total Assets (Q: Sep. 2012 ))	/ count )
=	0.061	/	( (9.712	+	7.805)	/ 2 )
=	0.061	/	8.7585
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Audeo Oncology Total Assets Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Total Assets

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.